CYD dengue vaccine serotypes (1, 2, 3, 4). + Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dengue Virus
Conditions
Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Disease
Trial Timeline
Mar 1, 2009 → Dec 1, 2014
NCT ID
NCT00875524About CYD dengue vaccine serotypes (1, 2, 3, 4). + Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide
CYD dengue vaccine serotypes (1, 2, 3, 4). + Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide is a phase 2 stage product being developed by Sanofi for Dengue Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT00875524. Target conditions include Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00875524 | Phase 2 | Completed |
Competing Products
20 competing products in Dengue Virus